The NCI Experimental Therapeutics (NExT) pipeline is designed to assist translation to the clinic of novel therapeutic interventions, either synthetic, natural product, or biologic, arising from academic, private, or government entities. NExT is not a grant mechanism. Approved proposals gain access to drug discovery resources and development resources through the NExT Program. A panel of experts will evaluate the applications based on criteria including scientific merit, feasibility, alignment with NCI mission, novelty, and clinical need. The NExT Program will send notification letters informing applicants of the evaluation result of their proposals four to six months after their submission deadline.
Application submissions occur in cycles and open (regardless of holidays or weekends) on January 15th, May 15th and September 15th of each calendar year and close one month later on February 15th, June 15th and October 15th .
Sponsor Institute/Organizations: National Institutes of Health
Address: National Institutes of Health; 31 Center Drive; MSC 2220; Bethesda; MD 20892-2220; USA
Oct 15, 2024
Varies
Affiliation: National Institutes of Health
Address: National Institutes of Health; 31 Center Drive; MSC 2220; Bethesda; MD 20892-2220; USA
Disclaimer:It is mandatory that all applicants carry workplace liability insurance, e.g., https://www.protrip-world-liability.com (Erasmus students use this package and typically costs around 5 € per month - please check) in addition to health insurance when you join any of the onsite Trialect partnered fellowships.